Tysabri (Natalizumab) Denied: Appealing RRMS Coverage With JC Antibody and DMT Failure

Tysabri (natalizumab) is an alpha-4 integrin inhibitor FDA-approved for relapsing forms of multiple sclerosis, including relapsing-remitting MS (RRMS) and, as monotherapy, for patients who have had an inadequate response to or cannot tolerate other MS therapies. It is also FDA-approved for moderately to severely active Crohn's disease in patients with inadequate response to conventional therapies. Tysabri is a high-efficacy MS treatment with a well-established but carefully managed risk profile, primarily the risk of progressive multifocal leukoencephalopathy (PML) caused by the JC virus. Insurance denials for Tysabri often center on this risk profile and on prior DMT failure requirements.

Why Tysabri Gets Denied

Prior DMT failure requirement. Most insurance plans require documented failure of at least one disease-modifying therapy before approving Tysabri. The FDA label positions Tysabri as a therapy for patients who have had an inadequate response to or cannot tolerate other MS therapies, and insurers use this language to enforce step therapy. Common required prior DMTs include interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, or siponimod.

JC antibody status concerns. Tysabri is associated with PML risk that is strongly correlated with JC antibody status and index value. Insurers do not deny coverage based on positive JC antibody status per se — the drug is approved for JC-positive patients under the TOUCH prescribing program — but some payers require documentation of JC serology testing before approving, and denials occur when this documentation is absent.

TOUCH Program compliance. Tysabri is only available through the TOUCH (Tysabri Outreach: Unified Commitment to Health) prescribing program, a REMS program requiring enrollment of patients, prescribers, and infusion centers. If any element of TOUCH enrollment is missing from the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization, insurers will deny on administrative grounds.

Monotherapy restriction. Tysabri is indicated as monotherapy; it should not be combined with other immunosuppressant or immunomodulatory medications. If the prescriber is requesting Tysabri alongside another DMT without transitioning off the prior therapy, the insurer may deny citing the monotherapy requirement.

Crohn's disease step therapy. For Crohn's, Tysabri requires documented failure of conventional therapies and is increasingly considered only after TNF inhibitor failure, though the label does not technically require TNF failure. Appeals for Crohn's indication should document the full IBD treatment history.

Documenting Prior DMT Failure

For RRMS appeals based on prior DMT failure, the documentation must include:

• Primary non-response: Patient had breakthrough relapses or new MRI activity while on adequate doses of prior DMT for a sufficient trial period (typically 6–12 months)
• Secondary loss of response: Initial benefit followed by return of disease activity
• Intolerance or adverse effects: Specific adverse events (flu-like symptoms requiring dose reduction, liver toxicity with interferon products, PML risk concerns with prior dimethyl fumarate, etc.)
• Contraindications: If a specific required drug was contraindicated, document the medical reason

MRI comparisons are particularly powerful: a report showing new T2 lesions or gadolinium-enhancing lesions while on prior therapy is objective evidence of treatment failure.

JC Antibody Management in Appeals

If your insurer or reviewer expresses concern about Tysabri's PML risk, your appeal should include:

Stratification by JC index value. JC antibody index > 0.9 confers higher PML risk than low-index positivity. If your index is low positive, document this and explain how prescriber monitoring protocols (extended interval dosing, periodic MRI surveillance) reduce PML risk to an acceptable level.

Extended interval dosing (EID). The FDA approved extended interval dosing (every 6 weeks instead of every 4 weeks) in 2020. Studies show EID reduces PML risk by approximately 94% in JC-positive patients with no prior immunosuppressant use. If EID is the prescriber's plan, include this in the appeal — it directly addresses the insurer's stated safety concern.

Benefit-risk assessment. For a patient with highly active RRMS (high relapse rate, rapid disability progression, significant MRI burden), the risk of untreated MS progression may substantially outweigh the PML risk, particularly with appropriate monitoring. Your neurologist's letter should frame this risk-benefit analysis explicitly.

Fight Back With ClaimBack

Tysabri denials are almost always addressable through proper documentation of prior DMT failure, JC status management, and TOUCH program compliance. ClaimBack helps you compile and organize the clinical evidence your insurer requires.

Start your Tysabri appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?